Amiodarone Plus Ranolazine

PreclinicalSmall molecule

Amiodarone Plus Ranolazine is one of 4 small molecule programs targeting Ventricular arrhythmia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventricular ArrhythmiaActive, not recruiting

Ventricular ArrhythmiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Ventricular Arrhythmia

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Xylocaine

Tambocor

1 4

Amiodarone Plus Ranolazine

HHartford Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ventricular arrhythmia1 trial

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

Completed·HHartford Hospital·N/A·NCT01480336·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amiodarone Plus Ranolazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amiodarone Plus Ranolazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amiodarone Plus Ranolazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hartford Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHartford Hospital

Amiodarone Plus Ranolazine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ventricular arrhythmia1 trial

References

Drug Info

Quick Facts

Related News